Novartis Pharmaceuticals

This study tests whether alpelisib can shrink lymphatic malformations (abnormal fluid-filled growths) in people with a specific PIK3CA gene mutation. About 232 children and adults will receive either alpelisib or a placebo. The main goal is to see if the growths shrink by at leas…

This study tests a new drug called ECI830, alone or with other cancer drugs, in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination shrinks tumors or delays growth. About 28…

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have a serious complication after a stem cell transplant called graft-versus-host disease (GvHD) that did not improve with steroids. The goal is to see if ruxolitinib can control the disease by reduci…

This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for adults with myelofibrosis, a rare bone marrow cancer. The study enrolls 460 people who have not taken JAK inhibitors before. The main goals are to shrink th…

This study monitors the safety and effectiveness of the drug Cosentyx in Korean patients with three conditions: hidradenitis suppurativa (painful skin boils), pediatric plaque psoriasis (scaly skin patches in children), and juvenile idiopathic arthritis (childhood arthritis). Abo…

This study tests an experimental drug called LXE408 in 130 adults with chronic Chagas disease who do not have severe organ damage. The goal is to see if the drug can clear the parasite from the blood for at least 6 months. Participants will receive either LXE408 or a placebo, and…

This study tests an experimental drug called EYU688 in 108 adults with dengue fever. The goal is to see if it can lower the amount of virus in the blood and help fever go away sooner compared to a placebo. Participants must have had a fever for 48 hours or less and test positive …

This study tests a daily pill called iptacopan for people with generalized myasthenia gravis, a condition causing muscle weakness. About 146 adults will receive either iptacopan or a placebo for 6 months, while continuing their usual treatments. The goal is to see if iptacopan im…

This study tests an experimental drug called remibrutinib in people with secondary progressive multiple sclerosis (SPMS), a form of MS where symptoms steadily worsen. The goal is to see if the drug can delay disability progression. About 1,275 adults aged 18-65 with SPMS will tak…

This study looks at how patients with Familial Mediterranean Fever (FMF) or Still's disease (including juvenile and adult forms) are treated with the drug canakinumab (ILARIS) in real-world clinics across Europe and Israel. Researchers will track 160 people who have been on the d…

This study tests a new treatment called rapcabtagene autoleucel (a CAR-T cell therapy) against standard care for people with severe active vasculitis (GPA or MPA). About 126 adults aged 18–75 with confirmed ANCA antibodies and active disease will be enrolled. The goal is to see i…

This study tests a new treatment called DJI136, which uses a patient's own immune cells (T-cells) that are modified to target a protein (DLL3) found on small cell lung cancer cells. The trial is for adults with extensive-stage small cell lung cancer that has worsened after standa…

This study tests an oral drug called iptacopan in 31 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety. Participants take the …

This study tests a new radioactive drug (177Lu-DOTA-TATE) plus standard hormone therapy against standard therapy alone in 240 people newly diagnosed with advanced neuroendocrine tumors of the gut or pancreas. Participants must have slow-growing tumors with a high disease burden. …

This study tests a one-time cell therapy called rapcabtagene autoleucel against the standard drug rituximab in 96 people with severe, hard-to-treat scleroderma. The goal is to see if the new treatment can improve skin hardening, lung function, and quality of life better than the …

This study tests a new medicine called EDI048 in healthy adults who are given a controlled infection of cryptosporidiosis, a parasite that causes diarrhea. The goal is to see if EDI048 can reduce the severity and length of diarrhea. About 96 participants will take part, and the r…

This study is for adults with a rare blood disorder called aHUS who are currently receiving antibody infusions. Researchers want to see if switching to a daily pill called iptacopan is safe and works just as well to prevent dangerous blood clots. About 50 participants will take i…

This program provides ribociclib (LEE011) to people with serious or life-threatening breast cancer who have no other treatment options and cannot join a clinical trial. It is only available through a doctor's request and aims to offer potential benefit when standard therapies are…

This early-stage study tests whether adding pelabresib to the standard drug ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and measure drug levels. The goal is to fi…

This phase 3 study tests whether the drug votoplam can slow the progression of Huntington's disease in people with early symptoms. About 770 adults aged 21 to 70 with confirmed Huntington's will receive either votoplam or a placebo. The main goal is to see if votoplam helps maint…

This study tests an experimental drug called MAS825 in 20 people (ages 1 and up) with Still's disease, a rare inflammatory condition. The goal is to see if the drug can control symptoms like fever, rash, and joint pain. Participants will receive the drug and be monitored for resp…

This study tests whether adding a new drug (JSB462) to standard hormone therapy (abiraterone) can better control metastatic hormone-sensitive prostate cancer. About 150 men with high-volume disease will receive either the combination or another standard treatment. The goal is to …

This study looks at the long-term safety of a drug called ianalumab for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It is for those who have already completed a previous ianalumab study. About 550 participants will receive either the drug or a pl…

This study is checking the long-term safety of a drug called pelacarsen in about 5,700 people with high levels of lipoprotein(a) and heart disease. Participants have already finished an earlier study of this drug. The main goal is to track side effects over time, not to test if t…

This study tests a new gene therapy called DFT383 in children aged 2 to 5 with nephropathic cystinosis, a rare disease that damages the kidneys and other organs. The treatment aims to fix the genetic problem and reduce or eliminate the need for daily medication. About 30 children…

This study tests a new drug called ianalumab in 200 adults with a severe form of scleroderma that affects the skin and internal organs. The goal is to see if it can improve skin hardening and lung function compared to a placebo over 52 weeks. Participants must be between 18 and 7…

This study tests a new drug called LTP001 for pulmonary arterial hypertension (PAH), a condition where blood pressure in the lungs is too high. First, healthy volunteers will receive single or multiple doses to check safety and how the drug moves through the body. Then, people wi…

This study follows 30 children aged 1 to 18 with chronic heart failure who are taking Entresto for the first time. Researchers will monitor safety issues like low blood pressure, high potassium, kidney problems, and dehydration for up to 52 weeks. The goal is to understand how sa…

This study tests a new drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can slow down the disease by measuring changes in kidney tissue and other markers. Participants must have a confirmed diagnosis and persistent protein…

This study follows up to 100 people with cancers like melanoma, lung cancer, or rare tumors who are already benefiting from treatment with dabrafenib and/or trametinib. The goal is to monitor long-term safety and side effects while patients continue their medication. Participants…

This study tests whether adding the drug ianalumab to a standard platelet-boosting therapy is safe and tolerable for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants must have tried 1 to 4 pr…

This early-stage study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjögren's disease. The main goal is to check safety and how the therapy behaves in the body. Participants must have failed standa…

This study offers ongoing access to crizanlizumab for people with sickle cell disease who were already benefiting from the drug in a previous Novartis trial. About 130 participants will continue treatment while researchers monitor safety. The goal is to provide uninterrupted care…

This study tests an experimental drug, 177Lu-FAP-2286, that delivers radiation directly to cancer cells in people with advanced solid tumors. The drug targets a protein called FAP found on cells surrounding many tumor types. The trial has two parts: first, finding a safe dose, th…

This early-stage study tests a new drug called INR731, alone or with standard hormone therapy, in adults with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Ab…

This study tests an oral drug called asciminib in children (ages 1 to under 18) with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP) who have already tried other treatments. The goal is to find the right dose that works like it does in adults and to check i…

This study tests a new drug (177Lu-NeoB) that delivers radiation directly to cancer cells, combined with the chemotherapy capecitabine, in people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The …

This early-stage study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3. It is for adults with advanced small cell lung cancer, neuroendocrine prostate cancer, or related tumors that have not responded to standard treatments. The main g…

This study tests a daily oral drug called alpelisib in children and adults with PROS, a rare condition causing abnormal tissue growth. The goal is to see if the drug can shrink overgrowths and improve symptoms. Participants must be at least 2 years old and have active, worsening …

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study follows 200 adults in Spain who are already taking inclisiran (Leqvio) for heart disease or a genetic high-cholesterol condition. Researchers want to see if the drug helps patients reach their LDL cholesterol goals in everyday medical practice. The study is observation…

This study tests whether adding pelacarsen to standard care (including inclisiran) can safely lower high levels of lipoprotein(a), a genetic risk factor for heart attacks and strokes. About 340 adults with established heart or blood vessel disease will receive either pelacarsen o…

This early-stage study tests a new drug called ITU512 in healthy people and those with sickle cell disease. The goal is to see if it is safe and can increase fetal hemoglobin, which may reduce sickle cell complications. About 161 participants will take part, starting with healthy…

This study tests new investigational drugs for people with moderate to severe atopic dermatitis (eczema). About 224 adults will receive either the study drug or a placebo. The main goal is to see if the drug reduces eczema severity, measured by a standard skin score, after 16 wee…

This program provides access to secukinumab (AIN457) for people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or use available therapies. Doctors must request access on behalf of their p…

This early-stage study is testing a new drug called PIT565 in 54 adults with active lupus who haven't gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Researchers will monitor side effects and measure drug levels i…

This study is observing about 177 people in Saudi Arabia with HR+/HER2- early breast cancer who are already taking ribociclib plus hormone therapy as part of their routine care. Researchers will track how long patients stay free from cancer returning and note any side effects. Th…

This study tests a new medicine called QCZ484, given as a shot under the skin every 6 months, to see if it safely lowers blood pressure in adults with mild to moderate hypertension. About 380 participants will receive either QCZ484 or a placebo for 12 months. The main goal is to …

This study tests whether giving the cholesterol-lowering drug inclisiran soon after a heart attack can reduce the risk of another heart attack, stroke, or related hospital stay. About 300 adults in Russia who had a heart attack and have high cholesterol will receive inclisiran ea…

This study tests a drug called inclisiran in children aged 6 to 12 who have a genetic condition that causes very high cholesterol. The goal is to see if the drug safely lowers their bad cholesterol levels. Participants will receive either inclisiran or a placebo for one year, the…

This study follows about 3,280 adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger) to see how well remibrutinib works in real-world clinics. Participants either stay on standard antihistamines or switch to remibrutinib, based on their doctor's dec…

This study looks at how well the drug asciminib works and is tolerated in adults with a type of blood cancer called chronic myeloid leukemia (CML). It includes both newly diagnosed patients and those who have already tried one other treatment. Researchers will track how many pati…

This study tests a drug called asciminib in children aged 1 to 18 with a specific type of leukemia (Ph+ CML-CP). The goal is to see if the drug can reduce cancer cells to very low levels. About 50 children will take the drug daily, either as a liquid or pill. This is not a cure, …

This study tests whether the drug inclisiran can reduce fatty plaque buildup in heart arteries after a heart attack. About 334 adults with high cholesterol and a recent heart attack will receive inclisiran or standard care. Doctors will use special imaging to measure plaque chang…

This study tests whether adding the drug iptacopan (LNP023) to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus). About 240 adults with biopsy-confirmed lupus nephritis will receive either iptacopan or a placebo alongside their usua…

This program provides access to asciminib (ABL001) for people with chronic-phase chronic myeloid leukemia who have no other treatment options and cannot join a clinical trial. Doctors can request the drug for individual patients who may benefit. The goal is to offer a potential t…

This study is testing two doses of an inhaled medicine called glycopyrronium in children aged 6 to 12 with moderate to severe asthma. The goal is to see how well it opens up the airways and how safe it is compared to a placebo. The results will help decide the right dose for a fu…

This study follows 800 adults with relapsing multiple sclerosis in Germany to see how long they continue their prescribed injectable or oral treatments. Researchers will collect data from medical records and questionnaires over up to four years. The goal is to understand real-wor…

This study tests a new medicine called DII235 in 200 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease. Participants will receive either the drug or a placebo to see if DII235 safely lowers these levels over 6 to 12 months. The goal is to find the…

This study tests a new drug called FWY003 in people with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. The goal is to see if different doses can slow the growth of damaged areas in the eye. About 272 adults aged 50 and older wil…

This study tests whether people with relapsing multiple sclerosis can safely switch from the infusion ocrelizumab to the experimental pill remibrutinib. About 360 adults aged 40-70 will be randomly assigned to either switch or stay on ocrelizumab. The goal is to see if remibrutin…

This study tests a monthly injection called pelacarsen to see if it can slow the worsening of a heart valve condition called aortic stenosis. The valve becomes stiff and narrow due to calcium buildup, making it harder for the heart to pump blood. The trial includes 502 adults age…

This study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already taken part in earlier studies will continue treatment to see if their kidney function s…

This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer or other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can help control the disease. About 205 ad…

This study is a required safety check for the asthma inhaler Enerzair, already approved for use. It will follow 600 adults with asthma for 24 weeks to see how well the drug works and what side effects occur in everyday medical practice. The goal is to confirm the drug's safety an…

This study looks at how well and how safely the drug asciminib works for people newly diagnosed with a type of leukemia called chronic myeloid leukemia (CML). About 200 adults in China will take the drug and be followed for at least 12 months. The main goal is to see how many ach…

This study tests a new drug, iptacopan, for people with a rare kidney disease called C3G. The goal is to see if it can reduce protein in the urine and protect kidney function better than a placebo. About 98 participants aged 12 to 60 will take the drug or a placebo for up to 12 m…

This study is for people with chronic myeloid leukemia (CML) who have already been helped by the drug asciminib in a previous Novartis study. It aims to track long-term safety and side effects while allowing patients to keep taking the medication. About 347 participants will be m…

This study tests a new drug (AAA817) that delivers radiation directly to prostate cancer cells, combined with standard hormone therapy, in men with advanced prostate cancer that no longer responds to hormone treatment alone. About 940 adults will be randomly assigned to receive e…

This study is checking how safe and effective Pluvicto is for men with advanced prostate cancer that no longer responds to hormone therapy. About 278 participants in South Korea will be followed during their regular treatment. The main goal is to track any side effects and see ho…

This study tests a drug called inclisiran in children aged 2 to 12 who have a rare genetic condition causing very high cholesterol. The goal is to see if the drug safely lowers their bad cholesterol compared to a placebo over one year. All participants will receive the drug in th…

This study follows children who have already taken dabrafenib and/or trametinib for certain brain tumors. Researchers will monitor side effects and track growth over time. The goal is to understand the long-term safety of these medications in young patients.

This study tests whether a new combination of two drugs (tulmimetostat and luxdegalutamide) can help men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. About 188 men will take part across two phases: first to find the safest dose…

This study tests an experimental drug called NIO752 in 300 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. Participants will receive either the drug or a placebo, and later everyone can get the real drug. The goal is to se…

This program provides eltrombopag, a drug that raises platelet counts, to patients with serious or life-threatening thrombocytopenia who have no other treatment options and cannot join a clinical trial. Doctors must request the drug for individual patients who may benefit. The go…

This early-phase study tests a new treatment called YTB323, a CAR-T cell therapy, for people with generalized myasthenia gravis that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease. About 15 participants will receive the…

This study watches how safe and effective two targeted drugs (dabrafenib and trametinib) are for people with advanced or recurrent solid tumors that have a specific genetic change (BRAF V600E). About 110 adults and children will be followed to track side effects and tumor shrinka…

This study tests a new drug, iptacopan, for people with a rare kidney disease called IC-MPGN. The goal is to see if the drug can reduce protein in the urine and help protect kidney function. About 106 adults and teens will take either iptacopan or a placebo for up to 18 months. T…

This study tests a one-time cell therapy called rapcabtagene autoleucel for people with active lupus that hasn't improved with standard treatments. About 179 adults will receive the therapy after a short course of chemotherapy to prepare their bodies. The goal is to see if the tr…

This study looks at the long-term safety of a drug called inclisiran in children with a genetic condition that causes very high cholesterol (familial hypercholesterolemia). About 195 kids who already completed earlier studies will receive inclisiran and be monitored for side effe…

This study tests a drug called asciminib in people with a specific type of chronic myeloid leukemia (CML) that has a genetic change called T315I. This change makes the leukemia harder to treat with standard drugs. The study includes about 20 adults whose cancer did not respond to…

This program provides early access to the drug EXV811 (atrasentan) for people with IgA nephropathy, a serious kidney disease, who have no other treatment options. It is for patients who cannot join a clinical trial and whose doctor requests the drug. The goal is to offer potentia…

This study tests whether adding ribociclib to standard hormone therapy can help prevent breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 adults with stage II or III disease will receive the combination for up to 3 years. The main goal is to s…

This study follows 40 adults in Saudi Arabia with chronic-phase CML who have already tried two or more TKIs. Researchers will track how well asciminib controls the cancer, its side effects, and how it affects daily life. The goal is to see if this medication works in real-world s…

This program provides access to tisagenlecleucel (CTL019), a CAR-T cell therapy, for people with serious blood cancers like lymphoma or leukemia who have no other treatment options and cannot join a clinical trial. Doctors must request the therapy for individual patients, and the…

This study tests a new drug called remibrutinib for teenagers aged 12 to 17 who have chronic hives (itchy welts) that don't get better with standard allergy pills. The goal is to see if the drug reduces itching and hives better than a placebo. Participants may continue the study …

This study is for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests how a radioactive drug (lutetium (177Lu) vipivotide tetraxetan) behaves in the body and its safety, especially in those with moderate or severe kidney…

This study looks at the long-term safety of a drug called pelacarsen in people with high levels of Lp(a) and heart disease. About 600 adults who finished a previous pelacarsen study can join. Researchers will track side effects and how well the drug lowers Lp(a) over time.

This program provides access to the experimental drug VAY736 (ianalumab) for patients with serious or life-threatening immune conditions like primary immune thrombocytopenia or Sjögren's syndrome. It is only available when no other treatments work and the patient cannot join a cl…

This study looks at the long-term safety of a drug called iptacopan in adults with primary IgA nephropathy, a kidney disease. Participants must have completed a previous iptacopan study. They will receive the drug openly (everyone knows they are getting it) until it becomes comme…

This study tests a drug called crizanlizumab to see if it can reduce the number of painful crises (called vaso-occlusive crises) in people with sickle cell disease. About 315 teens and adults who have frequent crises will receive either the drug or a placebo, and some may also ta…

This early-stage study tests a new drug called OJR520 in healthy people and those with chronic kidney disease. The main goal is to check if the drug is safe and how the body processes it. About 112 participants will receive either the drug or a placebo. This research is the first…

This study tests a new drug called remibrutinib for people with moderate to severe hidradenitis suppurativa, a condition causing painful lumps under the skin. About 555 adults and teens will take either one of two doses of the drug or a placebo for 68 weeks. The goal is to see if…

This program provides Lamprene (clofazimine), a drug originally approved for leprosy, to adults with NTM infections who have no other treatment options. Patients must be 18 or older and have failed or cannot tolerate standard therapies. The drug is given under an expanded access …

This study tests whether a targeted lipid optimization program helps adults in Abu Dhabi who are at high risk for heart disease reach their LDL (bad) cholesterol goals. About 326 participants will be randomly assigned to the program or usual care. The goal is to see if the progra…

This study tests an experimental oral drug, PKN605, to see if it can reduce the amount of time people with atrial fibrillation spend in an irregular heart rhythm. About 165 adults with a history of atrial fibrillation will receive either the drug or a placebo. The main goal is to…

This study tests a longer course of a targeted radiation drug (lutetium-177) in adults with a type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if giving up to 12 cycles is safe and how the radiation affects the body. About 106 pa…

This study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose manufactured cell therapy (tisagenlecleucel) didn't meet commercial release standards. The goal is to check if this slightly off-spec product is still safe and effective. Abou…

This study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. The goal is to see if the drug remains safe and helpful over time.

This study tests whether starting the drug inclisiran early in the hospital can lower bad cholesterol more than a placebo in people with acute coronary syndrome (a serious heart condition). About 300 adults hospitalized for a heart attack or unstable angina will receive either in…

This study tests an experimental drug called GIA632 for adults with non-segmental vitiligo, a condition that causes white patches on the skin. About 210 participants will receive either the drug or a placebo to see if it can help restore skin color and to find the best dose. The …

This program gives adults with chronic spontaneous urticaria (long-term hives) access to remibrutinib, an experimental drug. It is for people whose hives did not improve with standard treatments like antihistamines or omalizumab. The goal is to control symptoms and improve qualit…

This early-stage study tests an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis whose disease has worsened even while on strong treatments. The goal is to check if YTB323 is safe and can control the disease. Participants receive a sing…

This study tests whether adding a new drug called inclisiran to standard care can lower 'bad' cholesterol more than standard care alone in people who have recently had a heart attack, stroke, or urgent heart procedure. About 520 adults will be randomly assigned to receive either …

This study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much PSA levels drop, how long the cancer stays controlled, and how patients feel during and up to a year after treatment. The …

This study tests an experimental drug called remibrutinib against a placebo in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants must already be on standard treatments. The main goal is to see if the drug improves daily activities ov…

This study tests a second round of ianalumab in 60 adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who previously responded to the drug. The goal is to see if retreatment can control the disease again after it returns. Partic…

This study offers continued treatment with remibrutinib to people who have already completed a Novartis-sponsored study of the drug and are benefiting from it. Up to 212 participants will receive the treatment for up to three years while researchers monitor long-term safety. The …

This study tests a new drug (AMO959) combined with a targeted radiation therapy (177Lu-PSMA-617) and a standard hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to initial hormone treatment. The goal is to s…

This study follows 142 Canadian adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are prescribed secukinumab as part of their routine care. Researchers will track changes in disease severity over 12 months using a standar…

This study tests a new drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has stopped responding to standard treatments like hormone therapy, chemotherapy, and a targeted radiation therapy. About 443 participants will be randomly as…

This study tests a radioactive drug (lutetium-177 vipivotide tetraxetan) in men with prostate cancer that has spread to a few spots after initial treatment. The goal is to see if it can delay the cancer from spreading further and postpone the need for hormone therapy. About 450 m…

This study looks at how the drug secukinumab works in children aged 2 to 17 with juvenile psoriatic arthritis, a condition causing joint pain and skin patches. Researchers will measure drug levels in the blood and watch for side effects over up to 6 years. The goal is to understa…

This study is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who have never used certain biologic drugs. It will test how well secukinumab works and how safe it is. About 70 participants will be observed over time to see if their symptoms and …

This study looks at whether a mobile app can help people with hormone-receptor-positive, HER2-negative stage II or III breast cancer stick to their prescribed treatment of ribociclib plus an aromatase inhibitor. About 240 participants will either use the app or not, and researche…

This study looks at how well a new drug, remibrutinib, controls chronic hives (CSU) in everyday medical practice. About 505 adults whose hives are not controlled by standard antihistamines will be followed for 24 months. Researchers will track hive activity and control scores to …

This program provides access to the drug alpelisib (BYL719) for patients with serious conditions like PIK3CA-related overgrowth spectrum (PROS) or breast cancer who have no other treatment options and cannot join a clinical trial. It is not a standard study but a managed access p…

This program offers early access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like myelofibrosis, severe COVID-19, and graft-versus-host disease who have no other treatment options. It is for people who cannot join a clinical trial and…

This study looks at the long-term safety and how well the drug iptacopan works for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS). About 65 adults who already finished a previous iptacopan study and are still benefiting from the drug will conti…

This study looks at the long-term safety of secukinumab in up to 1,000 people with autoimmune or inflammatory conditions who finished a previous Novartis trial and still need the drug. Participants will continue receiving secukinumab and be monitored for side effects. The goal is…

This early-phase study is testing a new drug combination for people with a specific type of advanced breast cancer (ER+, HER2-) that has stopped responding to standard hormone therapy. The treatment adds a targeted radioactive drug (177Lu-NeoB) to two existing hormone-blocking me…

This study looks at the safety and effectiveness of Revolade (eltrombopag) in children aged 6 to 17 with aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. The children in this study have not been treated with anti-thymocyte globulin (ATG) before.…

This study looks at how well the drug ofatumumab (Kesimpta) controls relapsing multiple sclerosis (MS) in everyday medical care in Greece. About 160 adults with MS who have been taking ofatumumab for 3 to 6 months will be followed to see if they have no signs of disease activity,…

This early-stage study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see …

This program provides crizanlizumab (SEG101) to people with sickle cell disease who have no other treatment options and cannot join a clinical trial. It is for patients with serious or life-threatening conditions where the potential benefit outweighs the risks. The goal is to off…

This observational study follows about 3,250 people with HR+/HER2- early breast cancer who are at high risk of the cancer coming back. Researchers are watching how well Kisqali (ribociclib) plus an aromatase inhibitor works in everyday medical practice, checking safety, how well …

This study tests a drug called iptacopan in 12 children (ages 2 to 18) with a rare blood disease called PNH. The main goals are to see how the drug moves through the body and if it is safe. Participants will take the drug and be monitored for side effects and changes in their blo…

This study watches how well the drug Ilaris works and how safe it is for children and adults with rare hereditary fever syndromes (like CAPS, FMF, TRAPS, HIDS/MKD) and a type of childhood arthritis called sJIA. About 25 people will be followed during their regular treatment. The …

This study tests a combination of two targeted drugs, dabrafenib and trametinib, in people with rare solid tumors that have a specific genetic change (BRAF V600E) and cannot be removed by surgery or have spread. About 40 children and adults will receive the drugs to see how well …

This 2-year study looks at how well the drug ianalumab works for adults with lupus nephritis, a kidney disease caused by lupus. Some participants who already responded to treatment will stop the drug to see if they stay well, while others will continue or start open-label ianalum…

This study is tracking 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it controls the disease in everyday medical practice. The study will monitor infections, side effects, and k…

This early-phase trial tests a new treatment called YTB323 in 28 adults with non-active progressive multiple sclerosis (MS). The goal is to check if the therapy is safe and to see how it affects disability and disease progression. Participants receive a single dose, and researche…

This study tests two experimental drugs, remibrutinib (a pill) and dupilumab (an injection), in adults with chronic hives that antihistamines can't control. About 400 participants will receive one of the treatments for 4 weeks to see which works faster at reducing itch and hives.…

This early-stage study tests a new drug called JSB462 in 15 Japanese men with metastatic prostate cancer that has spread to bones or organs. The main goal is to check the drug's safety and how the body processes it. Participants must have tried or refused standard treatments. The…

This study looks at how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track changes in hemoglobin levels and other health outcomes over time. About 80 participants in China who have never taken sim…

This study is observing 600 Korean adults with chronic myeloid leukemia who are taking Scemblix (asciminib) as part of their regular care. Researchers will track side effects and how well the drug controls the disease over time. The goal is to see how the medicine performs outsid…

This study is a required safety check by Korean health authorities after Leqvio was approved. It will track 1500 adults with high cholesterol who are prescribed Leqvio in normal clinic visits. The goal is to see how safe and effective the drug is in real life, not in a controlled…

This study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (IIM) that haven't improved with standard therapies. IIM causes muscle weakness and inflammation. The treatment uses a patient's own immune cells that are mod…

This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard ca…

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGVHD) that did not improve with steroids. cGVHD is a complication after a stem cell transplant where the donor cells attack the patient's body. The main goal i…

This study is testing how well the drug ribociclib, combined with standard hormone therapy, prevents breast cancer from coming back in people with HR+ HER2- stage II or III breast cancer. About 2,766 participants in Russia will be followed for up to 5 years. The goal is to see if…

This program offers early access to the drug iptacopan for people with serious conditions like C3 glomerulopathy (a kidney disease) or paroxysmal nocturnal hemoglobinuria (a blood disorder) who have no other treatment options. Doctors can request the drug for patients who are not…

This study tests a new medicine called ianalumab for people with active lupus nephritis, a kidney problem caused by lupus. About 462 adults will receive either ianalumab or a placebo, added to their usual treatment. The goal is to see if ianalumab can help the kidneys work better…

This early-stage study tests a new drug called PIT565 in people with rheumatoid arthritis (RA). The main goal is to check if the drug is safe and how the body processes it. About 57 adults with RA will take part. The study is open-label, meaning everyone knows they are getting th…

This study looks at how well the drug iptacopan works for people with a rare blood disease called PNH. Researchers will track 50 patients in Italy for 12 months to see if their blood health improves and if they need fewer blood transfusions. The goal is to understand the drug's r…

This study tests two doses of a drug called remibrutinib against a placebo in 555 people aged 12 and older with moderate to severe hidradenitis suppurativa (HS), a condition causing painful lumps under the skin. The main goal is to see if the drug reduces the number of inflamed n…

This study compares a new combination inhaler (QMF149) to a standard asthma inhaler (budesonide) in 200 children aged 6 to 12 with asthma. Each child will try both treatments for 12 weeks to see which one improves lung function and symptom control more. The goal is to find a more…

This study tests an experimental drug called VHB937 in people with early Alzheimer's disease. The goal is to see if it can slow down memory and thinking problems. About 407 participants will receive either the drug or a placebo for 72 weeks, and researchers will track changes in …

This program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …

This study tests whether adding two simple questions about morning stiffness and lower back pain to a standard screening tool can help doctors spot psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults in Canada who are candidates for bi…

This early-stage study tests a new drug called EDK060 in adults with Charcot-Marie-Tooth type 1A (CMT1A), a genetic nerve disorder that causes muscle weakness. The main goal is to check if the drug is safe and how the body processes it. About 28 participants will receive either E…

This study is a survey of 77 adults in Saudi Arabia with moderate to severe hidradenitis suppurativa (HS) who are starting a new medication called Cosentyx (secukinumab). The goal is to see how satisfied patients are with the treatment after 24 weeks, focusing on convenience, sid…

This study tests a new drug called remibrutinib in 44 adults with chronic hives (either spontaneous or triggered by things like cold or pressure). The goal is to see if it reduces itching, pain, and burning better than a placebo over 12 weeks. Participants must have had hives for…

This study follows 500 men with metastatic castration-resistant prostate cancer who are receiving a targeted radiation therapy called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how the treatment affects their quality of life, pain, and disease progression in every…

This early-stage study tests the safety and tolerability of a new drug called HJB647 in 12 adults with stable heart failure and reduced pumping ability. Participants will receive two different doses of the drug or a placebo in a crossover design. The goal is to see if the drug is…

This study tracks 350 adults with chronic spontaneous urticaria (long-lasting hives) who are starting a new medication called remibrutinib. Researchers will use patient questionnaires to measure how well the drug controls symptoms like itching and swelling over the first month. T…

This study tests whether a new drug called GXV813 can safely reduce symptoms of schizophrenia during an acute episode. About 142 hospitalized adults aged 18-65 will receive either GXV813 or a placebo. The main goal is to see if the drug improves scores on a standard symptom scale…

This study looks at 30 people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel. Researchers will test tumor samples to see if the therapy played a role in causing the cancer. The goal is to better understand the risk, not to offer a new treatme…

This study follows about 175 people with spinal muscular atrophy who already received the gene therapy OAV101 in a previous trial. Researchers will check for serious side effects and track developmental milestones over 5 years. The goal is to understand the long-term safety and h…

This study looks at whether a blood test for a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 700 adults with MS in Germany will be observed for 24 months. The goal is to see h…

This study looks at how iptacopan affects the kidneys of 20 adults with IgA nephropathy, a kidney disease. Researchers will measure changes in kidney tissue and function over 9 months. The goal is to understand if the drug reduces immune system activity in the kidneys.

This study follows 250 Italian adults with moderate to severe hidradenitis suppurativa (HS) who are starting secukinumab. Researchers will collect data on how well the drug reduces skin abscesses and tunnels over time, as well as treatment patterns and healthcare costs. The goal …

This study follows 1,400 patients for 15 years after they received CAR T-cell therapy to check for delayed side effects, such as new cancers, infections, or nerve problems. Participants must have already been in a Novartis or University of Pennsylvania CAR T-cell trial. The goal …

This study looks at how the drug pelabresib is handled by the body in people with advanced cancer who also have liver issues. About 24 adults will take part to help researchers understand if liver function changes drug levels. The goal is to gather information for future dosing, …

This study is watching for side effects in 30 adults in Taiwan who are starting fingolimod for relapsing-remitting multiple sclerosis. Participants will be followed for one year to record any safety issues like slow heart rate, eye swelling, liver problems, or low white blood cel…

This study looks at how well the drug ribociclib works for people with early-stage breast cancer when used in regular medical practice. Researchers will track 3,000 patients to see if the cancer comes back and how patients feel about their treatment. The goal is to understand rea…

This study is collecting information from medical records of 14,000 people in China with a common type of advanced breast cancer (HR+/HER2-). The goal is to see which treatments doctors are actually using and how well they work in everyday practice, especially newer drugs like CD…

This study looks at ways to encourage doctors to test for Lp(a), a genetic risk factor for heart disease that often goes unchecked. About 4,500 adults in heart clinics will be involved, and researchers will compare testing rates before and after introducing new strategies. The go…

This study observes 300 adults with metastatic castration-resistant prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how long the treatment controls the cancer and any side effects in everyday medical practice, not in a controlled l…

This study looks at whether tracking eye movements can help doctors see how well multiple sclerosis (MS) treatment is working. About 224 Canadian adults with relapsing-remitting MS who are starting the drug ofatumumab will have their eye movements measured over time. The goal is …

This study follows 500 people in South Korea who have already received a treatment called tisagenlecleucel for certain blood cancers (like leukemia and lymphoma). The goal is to track long-term side effects, risk of new cancers, and how well the treatment works over time. No new …